Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT06656221
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06577025
- Locations
- 🇪🇸
Hosp Clinico Univ de Salamanca, Salamanca, Spain
🇪🇸Hosp. Univ. Marques de Valdecilla, Santander, Spain
🇺🇸City of Hope, Duarte, California, United States
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- North Estonia Medical Centre
- Target Recruit Count
- 50
- Registration Number
- NCT06505369
- Locations
- 🇳🇴
Oslo University Hospital, Oslo Myeloma Centre, Oslo, Norway
🇳🇴Stavanger University Hospital, Stavanger, Norway
🇩🇰Vejle hospital, Vejle, Denmark
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- Conditions
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06464991
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳People's Hospital of Peking University, Beijing, China
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 450
- Registration Number
- NCT06413498
- Locations
- 🇺🇸
UCLA Department of Medicine-Hematology/Oncology, Santa Monica, California, United States
🇺🇸Baptist Cancer Center, Memphis, Tennessee, United States
🇦🇺Epworth HealthCare, Richmond, Victoria, Australia
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Conditions
- Interventions
- Drug: DexamethasoneDrug: VincristineDrug: DaunorubicinDrug: Calaspargase pegolDrug: VenetoclaxDrug: BortezomibDrug: DasatinibDrug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)Drug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: NelarabineDrug: MethotrexateDrug: Thioguanine
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 145
- Registration Number
- NCT06390319
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 103
- Registration Number
- NCT06353022
- Locations
- 🇫🇷
CHU Montpellier, Montpellier, France
🇫🇷CH Lyon Sud, Lyon, France
🇫🇷CH de la Côte Basque, Bayonne, France
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT06348147
- Locations
- 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Bortezomib, Pomalidomide, Dexamethasone For Systemic AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Jin Lu, MD
- Target Recruit Count
- 40
- Registration Number
- NCT06342466
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Two Schemes Response in Multiple Myeloma
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Hospital General de Mexico
- Target Recruit Count
- 83
- Registration Number
- NCT06284395
- Locations
- 🇲🇽
Hospital General de Mexico Dr. Eduardo Liceaga, Mexico City, Cdmx, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.